The regulatory milestone follows comprehensive discussions regarding the content and structure of the application. Health Canada indicated no objections to the proposed timeline, clearing the path for the company to move forward with the administrative screening and subsequent scientific evaluation. Chief Executive Officer Alon Ben-Noon described the alignment as a pivotal operational target, noting that the company is currently finalizing clinical, biomarker, and manufacturing data to support the filing.
PrimeC is an extended-release oral formulation intended to slow the progression of ALS by targeting neuroinflammation, oxidative stress, and iron metabolism. The upcoming submission will draw on evidence from the Phase 2b PARADIGM study, which reported a statistically significant 15-month median survival benefit and consistent effects on disease progression markers. While NeuroSense prepares for the Canadian filing, it is also advancing the PARAGON study, a confirmatory Phase 3 trial. With approximately 3,000 people living with ALS in Canada and limited existing therapies, the company views the market as a significant opportunity to provide a new therapeutic intervention for a disease that remains fatal within two to five years of diagnosis.
Comments (0)
No comments yet. Be the first!